Overview

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After A

Status:
Recruiting

Trial end date:
2032-07-04

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).

Phase:

Phase 3

Details

Lead Sponsor:

Celgene

Collaborator:

Bristol-Myers Squibb

Treatments:

Cyclophosphamide
Fludarabine
Idecabtagene vicleucel
Lenalidomide